FDA Clearance Tracker · P150048-S097
TRIFORMIS RESILIA Tricuspid Valve, Model 11300T
Last checked: Nov 20, 2026Latest source record: Feb 6, 2026 (this decision)Source: openFDAMethods & limitations
Decided
Feb 6, 2026
Approved
Time to decision
30 days
Received Jan 7, 2026. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track No User Fee
Device class
Class III
The decision
- FDA number
- P150048-S097
- Device name
- TRIFORMIS RESILIA Tricuspid Valve, Model 11300T
- Applicant
- Edwards Lifesciences, LLC
- Applicant location
- Irvine, CA
- Received
- Jan 7, 2026
- Decided
- Feb 6, 2026
- Decision
- Approved
- Supplement type
- Normal 180 Day Track No User Fee
- Reason for supplement
- Postapproval Study Protocol
- Original approval
- P150048
Device type
- Device type
- heart-valve, non-allograft tissue (LWR)
- Device class
- Class III
- Specialty
- CardiologyInterventional Cardiology
FDA's approval statement
As written in FDA's record.
Approval of the protocol for the post-approval study (PAS) titled "EHR-Based New Enrollment Study." The PAS protocol was submitted to comply with the conditions of approval outlined in the approval order for P150048/S092.
Source documents
Other decisions for Edwards Lifesciences, LLC
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- PASCAL Precision Transcatheter Valve Repair SystemPMA supplement
P220003-S029 · Decided Oct 20, 2026 · 180 days after receipt · Panel Track
Device type: Tricuspid valve repair device, percutaneously delivered (NPS) · Cardiology
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.